A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Inclusion Criteria:

- Histologically or cytologically documented locally advanced or metastatic UBC
(including renal pelvis, ureters, urinary bladder, and urethra)

- Representative tumor specimens as specified by the protocol

- Disease progression during or following treatment with at least one
platinum-containing regimen for inoperable, locally advanced or metastatic UBC or
disease recurrence

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy greater than or equal to (>/=) 12 weeks

- Measurable disease, as defined by RECIST v1.1

- Adequate hematologic and end organ function

- For women of childbearing potential, agreement to refrain from heterosexual
intercourse or use contraceptive methods that result in a failure rate of < 1% per
year during the treatment period and for at least 5 months after the last dose of
atezolizumab, 3 months after the last dose of vinflunine and 6 months from the last
dose of paclitaxel or docetaxel.

- For men, agreement to refrain from heterosexual intercourse or use contraceptive
methods that result in a failure rate of < 1% per year during the treatment period and
for at least 3 months after the last dose of vinflunine and 6 months from the last
dose of paclitaxel or docetaxel, and agreement to refrain from donating sperm

Exclusion Criteria:

- Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment

- Treatment with any other investigational agent or participation in another clinical
trial with therapeutic intent within 28 days prior to enrollment

- Active or untreated central nervous system (CNS) metastases as determined by computed
tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
prior radiographic assessments

- Leptomeningeal disease

- Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception
of those with a negligible risk of metastasis or death and treated with expected
curative outcome, or localized prostate cancer treated with curative intent and
absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer

- Pregnant and lactating women

- Significant cardiovascular disease

- Severe infections within 4 weeks prior to randomization

- Major surgical procedure other than for diagnosis within 4 weeks prior to
randomization

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy
to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the
atezolizumab formulation

- History of autoimmune disease

- Prior allogeneic stem cell or solid organ transplant

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
chest CT scan

- Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or
hepatitis C or tuberculosis

- Administration of a live, attenuated vaccine within 4 weeks prior to randomization

- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune
checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated
protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1) or anti-programmed
death-ligand 1 (anti-PD-L1) therapeutic antibodies